

1 Title: A national survey of early treatment seeking behavior among those with incident
2 SARS-CoV-2 infection

3

4 Authors: Noah Kojima¹, Matthew Brobeck², Vladimir Slepnev², and Jeffrey D. Klausner³

5

6 ¹Department of Medicine, University of California Los Angeles, Los Angeles, 90095

7 ²Curative Inc., San Dimas, CA

8 ³Departments of Population and Public Health Sciences, Medicine, and the COVID-19

9 Pandemic Research Center, University of Southern California, Keck School of Medicine,

10 Los Angeles, 90033

11

12

13

14

15

16

17

18

19 Keywords: COVID-19; SARS-CoV-2; Treatment seeking behavior

20

21 Corresponding Author Contact Information:

22 Department of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA

23 90095. Email: nkojima@ucla.edu

24

25 Abstract

26 Background: Despite effective means to treat SARS-CoV-2 infection, the early
27 treatment seeking behavior of those newly diagnosed with infection is not clear.

28 Methods: We surveyed users of a national SARS-CoV-2 testing company to assess the
29 frequency and correlates of early treatment seeking behavior for a positive test result.

30 We recruited adults (18 years or older) who had tested positive for SARS-CoV-2 by
31 PCR at a large clinical laboratory. To be eligible, individuals had to have a positive test
32 result within 7 days of enrollment. Surveys were anonymous and voluntary. We
33 collected data on demographic characteristics, general health care access and
34 utilization, awareness of treatment for COVID-19, treatment seeking behavior, and
35 treatments received. Descriptive statistics and odds ratios (OR) with 95% confidence
36 intervals (95% CI) were calculated on StataSE.

37 Results: Participants were surveyed from 3-7 January 2022: among the 15,991 who
38 viewed a survey request, 7,647 individuals were eligible and provided responses. The
39 median age of a respondent was 42 years (interquartile range: 32 to 54), 68.9% of
40 respondents were women, and respondents represented 33 different states, districts,
41 and territories. Among respondents, 23.1% reported they had sought treatment or
42 medical advice for their current COVID-19 diagnosis. Of those who were very aware of
43 treatment for COVID-19, 31.0% sought treatment versus 16.7% who were unaware (p-
44 value < 0.001). The odds of treatment seeking behavior were higher for those that were
45 contacted by a medical professional after their diagnosis (OR: 4.57 [95% CI: 3.89 to
46 5.37]), those with a primary doctor (OR: 2.94 [95% CI: 2.52 to 3.43]), those who self-
47 measured their oxygen saturation (OR: 2.53 [95% CI: 2.25 to 2.84]), and those over 65

48 years of age (OR: 2.36 [95% CI: 2.02 to 2.76]). There was no difference in those
49 seeking treatment based on heritage, ethnicity, prior COVID-19 diagnosis, state political
50 affiliation, or vaccination status. The odds of seeking treatment were lower among men
51 (OR: 0.88 [95% CI: 0.78 to 0.99]) and those without insurance (OR: 0.62 [95% CI: 0.52
52 to 0.72]). The most common treatment locations were clinics and most common
53 treatments were Vitamin C, Vitamin D, Zinc, Tylenol, and NSAIDs.
54 Conclusion: More public outreach is needed to raise awareness of the benefits of
55 treatment for COVID-19. We found that people who were more aware about treatment
56 for COVID-19 were more likely to seek medical advice or therapy. Efforts to increase
57 awareness might increase early treatment for SARS-CoV-2 infection. Increased
58 outreach with treatment facilitation from medical professionals and/or public health staff
59 to those with newly detected SARS-CoV-2 infections, particularly among those at
60 higher-risk of complications, might also be helpful.

61

62 Main Text (586/600)

63 COVID-19 continues to cause severe disease, hospitalization, and death. Despite
64 effective means to treat SARS-CoV-2 infection,¹⁻⁴ the early treatment seeking behavior
65 of those newly diagnosed with infection is not clear. We surveyed users of a national
66 SARS-CoV-2 testing company to assess the frequency and correlates of early treatment
67 seeking behavior for a positive test result.

68

69 We recruited adults (18 years or older) who had tested positive for SARS-CoV-2 by
70 PCR at a large clinical laboratory (Curative, San Dimas, CA). To be eligible, individuals
71 had to have a positive test result within 7 days of enrollment. Surveys were anonymous
72 and voluntary. We collected data on demographic characteristics, general health care
73 access and utilization, awareness of treatment for COVID-19, treatment seeking
74 behavior, and treatments received. Descriptive statistics and odds ratios (OR) with 95%
75 confidence intervals (95% CI) were calculated on StataSE (StataCorp, College Station,
76 TX). Chi-squared tests and linear regression analysis were used to compare categorical
77 variables and continuous variables between groups, respectively. Advarra granted the
78 study IRB exempt (Pro00059961).

79

80 Participants were surveyed from 3-7 January 2022: among the 15,991 who viewed a
81 survey request, 7,647 individuals were eligible and provided responses. The median
82 age of a respondent was 42 years (interquartile range: 32 to 54), 68.9% of respondents
83 were women, and respondents represented 33 different states, districts, and territories.
84 Among those surveyed, 66.7% identified as White, 30.6% as Hispanic, 12.1% as Black

85 or African American, 6.2% as Asian, and 1.2% as Pacific Islander or Native American.

86 Most respondents reported they were vaccinated (89.3%).

87

88 Among respondents, 23.1% reported they had sought treatment or medical advice for
89 their current COVID-19 diagnosis (Table 1). Of those who were very aware of treatment
90 for COVID-19, 31.0% sought treatment versus 16.7% who were unaware (p-value<
91 0.001). The odds of treatment seeking behavior were higher for those that were
92 contacted by a medical professional after their diagnosis (OR: 4.57 [95% CI: 3.89 to
93 5.37]), those with a primary doctor (OR: 2.94 [95% CI: 2.52 to 3.43]), those who self-
94 measured their oxygen saturation (OR: 2.53 [95% CI: 2.25 to 2.84]), and those over 65
95 years of age (OR: 2.36 [95% CI: 2.02 to 2.76]).

96

97 There was no difference in those seeking treatment based on heritage, ethnicity, prior
98 COVID-19 diagnosis, state political affiliation, or vaccination status. The odds of seeking
99 treatment were lower among men (OR: 0.88 [95% CI: 0.78 to 0.99]) and those without
100 insurance (OR: 0.62 [95% CI: 0.52 to 0.72]). The most common treatment locations
101 were clinics and most common treatments were Vitamin C, Vitamin D, Zinc, Tylenol,
102 and NSAIDs (Table 2).

103

104 Due to the timing of the survey, infection was most likely due to the Omicron variant of
105 SARS-CoV-2, which might be less severe in those with prior immunity.⁵ The most
106 commonly used treatments were over-the-counter medications for symptom relief. Few
107 had received therapies known to reduce risk of disease progression.^{4,6} There were also

108 continued reports of non-beneficial medication use, i.e., ivermectin and
109 hydroxychloroquine.

110
111 More public outreach is needed to raise awareness of the benefits of treatment for
112 COVID-19. We found that people who were more aware about treatment for COVID-19
113 were more likely to seek medical advice or therapy. Efforts to increase awareness might
114 increase early treatment for SARS-CoV-2 infection. Additionally, those who were
115 contacted by a health professional were more likely to seek treatment or medical advice
116 for COVID-19. Increased outreach with treatment facilitation from medical professionals
117 and/or public health staff to those with newly detected SARS-CoV-2 infections,
118 particularly among those at higher-risk of complications, might also be helpful.

119
120 **Declarations**

121 Declaration of competing interests

122 NK is a consultant for Curative. MB and VS are employed by Curative. JDK is an
123 independent consultant and serves as the Medical Director of Curative.

124

125 **Funding**

126 Curative Inc. and by a gift to the Keck School of Medicine of the University of Southern
127 California by the W.M. Keck Foundation.

128

129 **Acknowledgements**

130 To the participants that donated their time.

131

132 References

- 133 1. O'Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV
134 Antibody Combination to Prevent Covid-19. *N Engl J Med*. Sep 23 2021;385(13):1184-
135 1195. doi:10.1056/NEJMoa2109682
- 136 2. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with
137 SARS-CoV-2 Neutralizing Antibody Sotrovimab. *N Engl J Med*. Nov 18
138 2021;385(21):1941-1950. doi:10.1056/NEJMoa2107934
- 139 3. Whitley R. Molnupiravir - A Step toward Orally Bioavailable Therapies for Covid-
140 19. *N Engl J Med*. Dec 16 2021;doi:10.1056/NEJMe2117814
- 141 4. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment
142 with flvoxamine on risk of emergency care and hospitalisation among patients with
143 COVID-19: the TOGETHER randomised, platform clinical trial. *Lancet Glob Health*. Jan
144 2022;10(1):e42-e51. doi:10.1016/S2214-109X(21)00448-4
- 145 5. Christie B. Covid-19: Early studies give hope omicron is milder than other
146 variants. *BMJ*. Dec 23 2021;375:n3144. doi:10.1136/bmj.n3144
- 147 6. Mahase E. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of
148 serious illness, company reports. *BMJ*. Nov 8 2021;375:n2713. doi:10.1136/bmj.n2713
149

150 Table 1. Demographic characteristics, health care access and utilization, awareness of treatment and treatment seeking
 151 behavior for COVID-19 among a national cohort of survey respondents that recently tested positive for SARS-CoV-2
 152 infection, 3 January 2022 to 7 January 2022

Variable	Group (N)	% Sought Treatment
All	7,647	23.1%
Of those that sought treatment		
Age 65 years and under	6,876	21.3%
Age over 65 years*	771	39.0%
Female*	2,375	23.8%
Heritage		
American Indian or Alaskan Native	60	28.3%
Asian	472	21.0%
Black or African American	925	25.3%
Multiracial	343	22.5%
Native Hawaiian	28	14.3%
White	5,099	23.5%

Ethnicity		
Hispanic or Spanish Origin	2,343	22.5%
Not Hispanic or Spanish Origin	4,750	23.4%
Vaccinated	6,828	23.5%
Not Vaccinated	819	20.3%
Prior COVID	1,872	25.5%
Contacted by Health Department	2,432	24.6%
Asked about contact tracing	1,930	24.2%
Contacted by a medical professional*	678	53.5%
Has a primary doctor*	5,723	27.1%
Last saw primary doctor		
within 12 months*	4,466	30.1%
12 to 24 months	822	17.0%
over 24 months	411	14.1%
Type of insurance		
Private (e.g., United, Anthem, Blue Cross)	5,519	23.1%

Government (Medicare, Medicaid, Veterans Affairs)*	473	34.3%
Kaiser	406	30.5%
None	1,249	16.6%
Awareness of treatment for COVID-19		
Very aware*	2,125	31.0%
Aware	1,380	19.6%
Not very aware	1,496	25.4%
Somewhat aware	1,326	18.0%
Unaware	1,320	16.7%
Measure home oxygen saturation*	1,827	36.9%
Political affiliation of state or district		
Won for Biden	6,388	23.2%
Won for Trump	1,023	23.2%

153 *p-value < 0.001

154

155 Table 2. Treatment locations and treatments used for COVID-19 among survey respondents who tested positive for
 156 SARS-CoV-2 infection in the prior 7 days, among 1767 persons reporting seeking treatment, 3 January 2022 to 7 January
 157 2022

Variable	Number	%
Location of treatment or medical advice		
Clinic	855	48.4%
Urgent Care	157	8.9%
Emergency Department	88	5.0%
Mobile Clinic	71	4.0%
Free Clinic	28	1.6%
Treatment used		
Vitamin C	825	46.7%
Vitamin D	685	38.8%
Zinc	636	36.0%
Acetaminophen (Tylenol)	546	30.9%
NSAIDs (e.g., Advil, Aleve, Motrin, or Ibuprofen)	522	29.5%

Azithromycin (Zithromax)	203	11.5%
Dexamethasone (Decadron) or prednisone*	179	10.1%
Aspirin	169	9.6%
Monoclonal antibodies**	100	5.7%
Ivermectin (Stromectol)	50	2.8%
Hydroxychloroquine (Plaquenil)	21	1.2%
Oxygen	14	0.8%
Nirmatrelvir/Ritonavir (Paxlovid; Pfizer)	13	0.7%
Fluvoxamine (Luvox, Faverin, Fluvoxin)	13	0.7%
Remdesivir (Veklury; Gilead)	10	0.6%
Convalescent plasma	2	0.1%
Colchicine (Colcrys)	2	0.1%
Molnupiravir (Lagevrio; Merck)	1	0.1%

158 *(Deltasone, Mericorten, Liquid Pred, Orasone) or inhaled budesonide (Pulmicort, Duoresp)

159 **(casiriviman-imdevimab [REGEN-COV]; REGENERON, sotrovimab [Xevudy]; GlaxoSmithKline, or bamlanivimab-

160 etesevimab; Eli Lilly)